Protagenic Therapeutics shares are trading lower. The company reported safety data from the single dose portion of its Phase 1 trial involving PT00114.
Portfolio Pulse from Benzinga Newsdesk
Protagenic Therapeutics shares are trading lower after the company reported safety data from the single dose portion of its Phase 1 trial involving PT00114.
May 22, 2024 | 5:01 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Protagenic Therapeutics shares are trading lower following the release of safety data from the single dose portion of its Phase 1 trial for PT00114.
The release of safety data from a clinical trial is a significant event for biotech companies. The market's negative reaction suggests that the data may not have met investor expectations, leading to a decline in share price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100